Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause

Rofo. 2017 May;189(5):423-430. doi: 10.1055/s-0042-122147. Epub 2017 Feb 2.


Purpose The purpose of this paper is the retrospective analysis of endovascular therapy for the treatment of superior vena cava syndrome (SVCS) of malignant cause. This study focuses on the effectiveness of the therapy regarding the duration of remission, symptom control and practicability. Materials and Methods From January 2003 to November 2012, therapeutic implantation of one or more stents was performed in 141 patients suffering from SVCS. The medical history was retrospectively researched using digitalized patient files. If those were incomplete, secondary research was conducted using the cancer registry of the General Hospital Nuremberg, the cancer registry of the tumor center at Friedrich-Alexander-University Erlangen-Nuremberg (FAU) or information given by physicians in private practice. This data was collected using Microsoft Office Excel® and statistically analyzed using IBM SPSS Statistics 22®. Results 168 stents were implanted in 141 patients (median age: 64.6 years; range: 36 - 84), 86 being male and 55 being female. In 121 patients, SVCS was caused by lung cancer (85.8 %), in 9 patients by mediastinal metastasis of an extrathoracic carcinoma (6.4 %), in 3 patients by mesothelioma of the pleura (2.1 %) and in 1 patient by Hodgkin's disease (0.7 %). There was no histological diagnosis in 7 cases (4.9 %). The primary intervention was successful in 138 patients (97.9 %). Immediate thrombosis in the stent occurred in the remaining 3 cases. Recurrence of SVCS was observed in 22 patients (15.6 %), including 5 early and 17 late occlusions. Stent dislocation or breakage was not observed. As expected, the survival after implantation was poor. The median survival was 101 days, and the median occlusion-free survival was 80 days. Conclusion The symptomatic therapy of SVCS with endovascular stents is effective and safe. Despite effective symptom control and a low rate of recurrence, the patients' prognosis is poor. Key Points: · Patients with SVCS of malignant cause have a poor prognosis.. · Lung cancer is the most common cause for SVCS.. · Endovascular therapy is safe and effective.. Citation Format · Büstgens FA, Loose R, Ficker JH et al. Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause. Fortschr Röntgenstr 2017; 189: 423 - 430.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Vessel Prosthesis / statistics & numerical data*
  • Comorbidity
  • Endovascular Procedures / instrumentation
  • Endovascular Procedures / methods
  • Endovascular Procedures / mortality
  • Female
  • Germany / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / mortality
  • Neoplasms / therapy
  • Prevalence
  • Prosthesis Implantation / methods
  • Prosthesis Implantation / mortality*
  • Risk Factors
  • Stents / statistics & numerical data*
  • Superior Vena Cava Syndrome / diagnostic imaging
  • Superior Vena Cava Syndrome / mortality*
  • Superior Vena Cava Syndrome / surgery*
  • Surgery, Computer-Assisted / methods
  • Surgery, Computer-Assisted / mortality*
  • Survival Rate
  • Treatment Outcome